Re: “Are Pre-Ascent Low-Altitude Saliva Cortisol Levels Related to the Subsequent Acute Mountain Sickness Score? Observations From a Field Study” by Gatterer et al.
Restricted accessResearch articleFirst published online September, 2020
Re: “Are Pre-Ascent Low-Altitude Saliva Cortisol Levels Related to the Subsequent Acute Mountain Sickness Score? Observations From a Field Study” by Gatterer et al.
BartschP, ShawS, FranciolliM, GnadingerMP, and WeidmannP. (1988). Atrial natriuretic peptide in acute mountain sickness. J Appl Physiol, 65:1929–1937.
2.
BergerMM, MacholzF, SarebanM, SchmidtP, FriedS, DanklD, NiebauerJ, BartschP, and MairbaurlH. (2017). Inhaled budesonide does not prevent acute mountain sickness after rapid ascent to 4559 m. Eur Respir J, 50:1700982.
3.
EstoppeyJ, LegerB, VuistinerP, SartoriC, and KayserB. (2019). Low- and high-altitude cortisol awakening responses differ between AMS-prone and AMS-resistant mountaineers. High Alt Med Biol, 20:344–351.
4.
GattererH, BernatzkyG, BurtscherJ, RainerM, KayserB, and BurtscherM. (2019). Are pre-ascent low-altitude saliva cortisol levels related to the subsequent acute mountain sickness score? Observations from a field study. High Alt Med Biol, 20:337–343.
5.
SwensonER. (2016). Pharmacology of acute mountain sickness: Old drugs and newer thinking. J Appl Physiol, 2:204–215.
